About P&T JournalContacts:
Statement of Purpose
Guidelines for Authors
Utilization of Health Care Resources in a High-Risk Medicaid Population with Chronic Obstructive Pulmonary Disease
The authors present a study in which they sought to identify patterns of disparities in race and sex in the use of health care resources by Medicaid patients with COPD, a population composed predominantly of minorities, women, and children.
Fadia T. Shaya, PhD, MPH, Antoine C. El Khoury, PhD, Navendu D. Samant, BS, PhD Candidate, and Steven M. Scharf, MD, PhD
Topics include therapies with atorvastatin for hypercholesterolemia and mixed dyslipidemia, aliskiren and darusentan for hypertension, perindopril for coronary artery disease, bivalirudin for acute coronary syndrome, atorvastatin for atrial fibrillation, and darbepoetin alfa and carvedilol for heart failure.
Lawrence M. Prescott, PhD, and Sharon L. Prescott
Dr. Goldenberg reviews advances in the treatment of lymphoma, including chemotherapeutic agents, monoclonal antibodies, radiolabeled products, and antisense drugs.
Marvin M. Goldenberg, PhD, RPh, MS
Continuing Education Credit
National Guidelines for a Novel Therapy: Update on Clinical Trials and Experience Using Consensus Panel Recommendations for Incorporating Omalizumab into Asthma Management
A panel of experts in allergies and pulmonology discuss the appropriate use of omalizumab with respect to current asthma guidelines and review the drug’s ability to improve symptoms, reduce exacerbations, and decrease patients’ use
of health care resources.
Mark J. Baumel, MD, Lawrence Du Buske, MD, Stanley J. Szefler, MD, Lanny Rosenwasser, MD, and David B. Nash, MD, MBA
David Nash, MD, MBA discusses the Canadian Coordinating Office for Health Technology Assessment, a source of information on drugs, devices, and “best practices” in Canada.
David Nash, MD, MBA
Matthew Grissinger, RPh, FASCP, alerts us to the confusion that can results when multiple, related errors occur simultaneously. Examples: when branded generic products are available from different manufacturers and when a drug is dispensed by its brand name and by its generic name to the same patient.
Matthew Grissinger, RPh, FASCP
Raging Hormones: Wyeth Hopes FDA Will Stop Compounding Pharmacies from Selling Bioidentical Hormones
Stephen Barlas comments on Wyeth’s petition to the FDA to stop compounding pharmacies from selling bioidentical hormones to women.
P&T presents the latest information about FDA approvals, drug indications, and devices.
Exenatide (Byetta), an Incretin Mimetic: The First in a New Therapeutic Class in the Treatment of Diabetes
The authors review exenatide (Byetta) for treating diabetes.
Sweta Chawla, PharmD